Chemical Component Summary

NameMILRINONE
Identifiers6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
FormulaC12 H9 N3 O
Molecular Weight211.22
TypeNON-POLYMER
Isomeric SMILESCC1=C(C=C(C(=O)N1)C#N)c2ccncc2
InChIInChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
InChIKeyPZRHRDRVRGEVNW-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count25
Chiral Atom Count0
Bond Count26
Aromatic Bond Count13

Drug Info: DrugBank

DrugBank IDDB00235 
NameMilrinone
Groupsapproved
DescriptionHeart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart failure is underpinned by numerous physiological changes, including alteration in β-adrenergic signalling and cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and cardiac output.[A228323] Milrinone is a second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of [amrinone].[A228333] As a PDE-III inhibitor, milrinone results in increased cAMP levels and improves cardiac function and peripheral vasodilation in acute decongested heart failure.[A228338, A11759, A228323, A228333, A228348, L31483] Milrinone was originally synthesized at the Sterling Winthrop Research Institute in the 1980s.[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]
Synonyms
  • 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
  • Milrinona
  • Milrinone lactate
  • Milrinone
  • Milrinonum
Brand Names
  • Milrinone Lactate Injection, USP
  • Milrinone Injection
  • Primacor Injection 1mg/ml
  • Milrinone Lactate Injection USP
  • Apo-milrinone Injectable
IndicationMilrinone is indicated for the short-term (48 hours or less) treatment of patients with acute decompensated heart failure. Milrinone administration should occur together with close monitoring using appropriate electrocardiographic equipment and should occur in a facility equipped for the immediate treatment of potential cardiac events, including ventricular arrhythmias.[L31483]
Categories
  • Amines
  • Aminopyridines
  • Cardiac Stimulants Excl. Cardiac Glycosides
  • Cardiac Therapy
  • Cardiotonic Agents
ATC-CodeC01CE02
CAS number78415-72-2

Drug Targets

NameTarget SequencePharmacological ActionActions
cGMP-inhibited 3',5'-cyclic phosphodiesterase AMAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDL...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDFILGEM
PubChem4197
PubChem5281020
ChEBICHEBI:50693
ChEMBLCHEMBL189
PharosCHEMBL189